Together, we can transform the lives of people with metastatic breast cancer.
As a collective of cancer nonprofits, pharmaceutical and biotech industry members and individual patient advocates, the Alliance serves as a national leader in collaborative action to transform and improve the lives of people living with metastatic breast cancer. We leverage the resources and knowledge of our dynamic group of trusted experts to increase awareness and education about the disease, and advocate for policy changes and increased funding for research that holds the potential to extend and enhance life – and ultimately end MBC.
How We Work
Our work to transform and improve the lives of people living with MBC is informed by real-world knowledge and data that identifies existing needs and opportunities.
VISION
We envision a world where all people living with metastatic breast cancer receive quality, individualized treatments to live long lives with a good quality of life, and where MBC is no longer a terminal illness.
MISSION
The mission of the Metastatic Breast Cancer Alliance is to amplify our collective efforts through collaboration & innovation to improve the lives of people living with metastatic breast cancer.
STRATEGIC GOALS
To realize our vision and mission, over the next five years we will pursue four strategic goals:
Research
Advocate to prioritize critical research to improve outcomes for all MBC patients.
Clinical Trials
Advocate for clinical trials to become more patient-centric by implementing patient-driven designs and procedures, removing barriers to participation, ensuring equity and diversity in recruitment, and supporting Alliance member clinical trial initiatives and materials.
Removing Barriers to Standard of Care
Ensure that all patients—regardless of race, ethnicity, age, gender, geographical location, sexual orientation, education level or ability to pay—have equitable access to quality standard of care including an appropriate clinical trial.
Quality of Life
Integrate Quality of Life services and care (i.e., palliative care, financial toxicity, shared decision making) into all treatment planning from initial diagnosis.
